CYDY News and Press, CytoDyn Inc From 06/21/21

CytoDyn ([[CYDY]]) announces preliminary results after unblinding the data from its COVID-19 long-haulers clinical trial.The purpose of the trial was to assess the safety and efficacy of leronlimab administered as weekly subcutaneous injection in subjects experiencing prolonged symptoms (>...

VANCOUVER, Washington, June 21, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) , ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today preliminary results af...

VANCOUVER, Washington, June 16, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today N...

The U.S. Food and Drug Administration (FDA) has historically refrained from providing confidential information regarding unapproved products to protect the trade secrets of drug developers. However, the agency made a stunning exception last month with the issuance of a statement regarding...

Leronlimab to be studied as potential HIV PrEP drug in humans through an early clinical trial VANCOUVER, Washington, June 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 a...

Are These 4 Penny Stocks On Your Watchlist This Week? Investing in penny stocks in 2021 has not been the easiest. With so many extraordinary events occurring and major uncertainty, finding the best penny stocks to buy is continuously a challenge. But like any good investor, util...

CytoDyn's COVID-19 efforts continue to be a battleground for bulls and bears. I believe that the bulls and bears need to come to terms with CytoDyn's programs and leronlimab's prospects. The company has moved beyond the U.S. FDA and is looking to conduct trials in other countries. How...

CytoDyn ([[CYDY]]) announces that Chiral Pharma in the Philippines placed its first purchase order for leronlimab under a Compassionate Special Permit (“CSP”) to treat critically ill COVID-19 patients in the Philippines.The company expects to recognize revenues re...

VANCOUVER, Washington, June 01, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab), a CCR5 antagonist with potential multiple therapeutic indications, anno...

Chiral is simultaneously working on application for Emergency Use Authorization VANCOUVER, Washington, June 01, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing VyrologixȒ...